Annual Cash & Cash Equivalents
$35.78 M
+$3.05 M+9.31%
31 December 2023
Summary:
Cidara Therapeutics annual cash & cash equivalents is currently $35.78 million, with the most recent change of +$3.05 million (+9.31%) on 31 December 2023. During the last 3 years, it has fallen by -$134.00 thousand (-0.37%). CDTX annual cash & cash equivalents is now -58.09% below its all-time high of $85.37 million, reached on 31 December 2016.CDTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$127.39 M
-$36.98 M-22.50%
30 September 2024
Summary:
Cidara Therapeutics quarterly cash and cash equivalents is currently $127.39 million, with the most recent change of -$36.98 million (-22.50%) on 30 September 2024. Over the past year, it has increased by +$78.72 million (+161.73%). CDTX quarterly cash and cash equivalents is now -22.50% below its all-time high of $164.37 million, reached on 30 June 2024.CDTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CDTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.3% | +161.7% |
| 3 y3 years | -0.4% | +248.0% |
| 5 y5 years | -52.0% | +72.5% |
CDTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -40.0% | +9.3% | -22.5% | +417.1% |
| 5 y | 5 years | -52.0% | +9.3% | -22.5% | +417.1% |
| alltime | all time | -58.1% | >+9999.0% | -22.5% | +458.8% |
Cidara Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $127.39 M(-22.5%) |
| June 2024 | - | $164.37 M(+466.4%) |
| Mar 2024 | - | $29.02 M(-18.9%) |
| Dec 2023 | $35.78 M(+9.3%) | $35.78 M(-26.5%) |
| Sept 2023 | - | $48.67 M(-3.5%) |
| June 2023 | - | $50.43 M(+5.1%) |
| Mar 2023 | - | $47.98 M(+46.6%) |
| Dec 2022 | $32.73 M(-45.2%) | $32.73 M(-38.3%) |
| Sept 2022 | - | $53.08 M(+115.4%) |
| June 2022 | - | $24.64 M(-32.5%) |
| Mar 2022 | - | $36.49 M(-38.9%) |
| Dec 2021 | $59.68 M(+66.2%) | $59.68 M(+63.1%) |
| Sept 2021 | - | $36.60 M(-24.2%) |
| June 2021 | - | $48.28 M(+12.6%) |
| Mar 2021 | - | $42.86 M(+19.4%) |
| Dec 2020 | $35.91 M(-28.6%) | $35.91 M(-21.1%) |
| Sept 2020 | - | $45.52 M(-17.0%) |
| June 2020 | - | $54.83 M(-14.8%) |
| Mar 2020 | - | $64.31 M(+27.9%) |
| Dec 2019 | $50.27 M | $50.27 M(-31.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2019 | - | $73.82 M(+65.6%) |
| June 2019 | - | $44.57 M(-22.4%) |
| Mar 2019 | - | $57.41 M(-23.0%) |
| Dec 2018 | $74.56 M(+22.6%) | $74.56 M(-11.0%) |
| Sept 2018 | - | $83.78 M(-5.8%) |
| June 2018 | - | $88.95 M(+70.4%) |
| Mar 2018 | - | $52.22 M(-14.1%) |
| Dec 2017 | $60.81 M(-28.8%) | $60.81 M(+12.0%) |
| Sept 2017 | - | $54.28 M(-30.4%) |
| June 2017 | - | $78.01 M(-5.1%) |
| Mar 2017 | - | $82.20 M(-3.7%) |
| Dec 2016 | $85.37 M(+36.5%) | $85.37 M(+246.7%) |
| Sept 2016 | - | $24.62 M(-15.9%) |
| June 2016 | - | $29.27 M(-43.4%) |
| Mar 2016 | - | $51.70 M(-17.4%) |
| Dec 2015 | $62.56 M(+174.4%) | $62.56 M(-3.0%) |
| Sept 2015 | - | $64.47 M(-47.3%) |
| June 2015 | - | $122.30 M(+110.4%) |
| Mar 2015 | - | $58.12 M(+155.0%) |
| Dec 2014 | $22.80 M(>+9900.0%) | $22.80 M |
| Dec 2013 | $185.00 K | - |
FAQ
- What is Cidara Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cidara Therapeutics?
- What is Cidara Therapeutics annual cash & cash equivalents year-on-year change?
- What is Cidara Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cidara Therapeutics?
- What is Cidara Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Cidara Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CDTX is $35.78 M
What is the all time high annual cash & cash equivalents for Cidara Therapeutics?
Cidara Therapeutics all-time high annual cash & cash equivalents is $85.37 M
What is Cidara Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, CDTX annual cash & cash equivalents has changed by +$3.05 M (+9.31%)
What is Cidara Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CDTX is $127.39 M
What is the all time high quarterly cash and cash equivalents for Cidara Therapeutics?
Cidara Therapeutics all-time high quarterly cash and cash equivalents is $164.37 M
What is Cidara Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, CDTX quarterly cash and cash equivalents has changed by +$78.72 M (+161.73%)